Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Headache Therapy (Butalbital Combination Agents) Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

- ☐ butalbital/acetaminophen (25 mg/325 mg)
- ☐ butalbital/acetaminophen (50 mg/300 mg)
- ☐ butalbital/acetaminophen (50 mg/325 mg)
- ☐ butalbital/acetaminophen/caffeine (50 mg/ 300 mg/40 mg)
- ☐ butalbital/acetaminophen/caffeine capsule (50 mg/325 mg/40 mg)
- ☐ butalbital/acetaminophen/caffeine tablet (50 mg/325 mg/40 mg) > 20 units/month, < 18 years of age
- ☐ butalbital/acetaminophen/caffeine solution
- ☐ butalbital/acetaminophen/caffeine/codeine (50 mg/300 mg/40 mg/30 mg)
- ☐ butalbital/acetaminophen/caffeine/codeine (50 mg/325 mg/40 mg/30 mg) > 20 units/month, < 18 years of age
- ☐ butalbital/aspirin/caffeine capsule (50 mg/325 mg/40 mg)
- ☐ butalbital/aspirin/caffeine tablet (50 mg/325 mg/40 mg) > 20 units/month, < 18 years of age
- ☐ butalbital/aspirin/caffeine/codeine (50 mg/325 mg/40 mg/30 mg)
- ☐ Other butalbital agent

Quantity requested per month

Dose, frequency, and duration of medication requested

Indication (Check all that apply or include ICD-10 code, if applicable.)

- ☐ Cluster headache. Frequency of headaches (number/month)
- ☐ Migraine headache. Frequency of migraine attacks (number/month)
- ☐ Tension headache. Frequency of headaches (number/month)
- ☐ Other. Specify pertinent medical history, diagnostic studies, and/or laboratory tests.

Section I. Please complete for butalbital agent requests exceeding quantity limits or for members < 18 years of age.

1. For migraine headache requests, has the member tried two triptans?
   ☐ Yes. Please list the drug names and outcomes below.

   Drug name ☐ Adverse reaction ☐ Inadequate response

   Briefly describe the details of adverse reaction or inadequate response.

Drug name ☐ Adverse reaction ☐ Inadequate response

Briefly describe the details of adverse reaction or inadequate response.

☐ No. Explain why triptans are not appropriate in this member.

2. For migraine headache requests, has the member tried an oral calcitonin gene-related peptide (CGRP) inhibitor?

☐ Yes. Please list the drug name and outcome below.

Drug name ☐ Adverse reaction ☐ Inadequate response

Briefly describe the details of adverse reaction or inadequate response.

☐ No. Explain why oral CGRP inhibitors are not appropriate in this member.

3. For both migraine and tension headache requests, is the member currently receiving prophylaxis?

☐ Yes. Please specify.

Drug name Dose and frequency

Drug name Dose and frequency

☐ No. Explain why prophylaxis is not appropriate in this member.

4. Is the member under the care of a neurologist? ☐ Yes ☐ No
5. Please list any other prior headache therapy trials. Please list the drug names and outcomes below.

Drug name ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug name ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, or other.

over

Section II. Please also complete for requests for butalbital/aspirin/caffeine capsule and butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg capsule.

Has the member tried butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg tablet?

☐ Yes. Please list the dates/duration of use and outcome below.

Dates/duration of use ☐ Adverse reaction ☐ Inadequate response ☐ Other Briefly describe details of adverse reaction, inadequate response, or other.

☐ No. Explain why butalbital 50 mg/acetaminophen 325 mg/caffeine 40 mg tablet is not appropriate in this member.

Section III. Please also complete for requests for all other butalbital agents that require PA and requests for codeine-containing products for members < 12 years of age.

Please provide clinical rationale for the requested agent. Please address the need for the requested agent instead of formulations available without PA, requested dosage formulation instead of conventional dosage forms, or use in the requested age group as appropriate.

Section IV. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.
2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.

over

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?

☐ Yes. Please provide details.

☐ No

Please continue to next page and complete Prescriber and Provider Information section.

over

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)